|

Nogapendekin Alfa Inbakicept Clinical Trials

2 actively recruiting trials across 2 locations

▲ +1 trial since June 2026

Also known as: ALT 803, ALT-803, ALT803, Anktiva, Fusion Protein Consisting of IL-15N72D and IL-15RASU/FC +10 more

Pipeline

Early 1: 1Phase 1/2: 1

Top Sponsors

  • Washington University School of Medicine1
  • Seth Pollack1

Indications

  • Cancer2
  • Round Cell Liposarcoma1
  • Non-small Cell Lung Cancer Recurrent1
  • Non-small Cell Lung Cancer Stage IV1
  • Myxoid Liposarcoma1

Chicago, Illinois1 trial

N-803 in Patients With Progressive Synovial Sarcoma and Myxoid/Round Cell Liposarcoma Previously Treated With Adoptive Cellular Therapy

Northwestern University

Early 1

St Louis, Missouri1 trial

First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer

Washington University School of Medicine

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.